1	Structural modeling for Oxford histological classifications of immunoglobulin A
2	nephropathy
3	
4	Short title: Structural modeling of immunoglobulin A nephropathy Oxford classification
5	
6	Kensuke Joh <sup>1*</sup> , Takashi Nakazato <sup>2</sup> , Akinori Hashiguchi <sup>3</sup> , Akira Shimizu <sup>4</sup> , Ritsuko
7	Katafuchi <sup>5</sup> , Hideo Okonogi <sup>6</sup> , Kentaro Koike <sup>7</sup> , Keita Hirano <sup>7</sup> , Nobuo Tsuboi <sup>7</sup> , Tetsuya
8	Kawamura <sup>7</sup> , Takashi Yokoo <sup>7</sup> , Ichiei Narita <sup>8</sup> , Yusuke Suzuki <sup>9</sup>
9	
10	<sup>1</sup> Department of Pathology, The Jikei University Graduate School of Medicine, Tokyo,
11	Japan
12	<sup>2</sup> Department of Medical information management, NHO Chiba Medical Center, Chiba,
13	Japan
14	<sup>3</sup> Department of Pathology, Keio University School of Medicine, Tokyo, Japan
15	<sup>4</sup> Department of Pathology, Nihon Medical School, Tokyo, Japan
16	<sup>5</sup> Kidney Unit, National Hospital Organization Fukuoka-Higashi Medical Center,
17	Fukuoka, Japan
18	<sup>6</sup> Division of Nephrology and Hypertension, Atsugi City Hospital, Kanagawa-ken,
19	Japan
20	<sup>7</sup> Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei
21	University School of Medicine, Tokyo, Japan
22	<sup>8</sup> Division of Clinical Nephrology and Rheumatology, Niigata University Graduate
23	School of Medical and Dental Sciences, Niigata, Japan
24	<sup>9</sup> Division of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 25 \*Corresponding author:

- 26 E-mail: johken@med.tohoku.ac.jp (KJ)
- 27

#### 28 Abstract

29 In immunoglobulin A nephropathy (IgAN), Cox regression analysis can select independent prognostic variables for renal functional decline (RFD). However, the 30 correlation of the selected histological variables with clinical and/or treatment variables 31 32 is unknown, thereby making histology-based treatment decisions unreliable. We prospectively followed 946 Japanese patients with IgAN for a median of 66 mo. and 33 applied structural equation modeling (SEM) to identify direct and indirect effects of 34 histological variables on RFD as a regression line of estimated glomerular filtration rate 35 (eGFR) via clinical variables including amount of proteinuria(UPE), eGFR, mean 36 arterial pressure(MAP) at biopsy, and treatment variables such as steroid therapy 37 with/without tonsillectomy(ST) and renin-angiotensin system blocker (RASB). 38 Multi-layered correlations between the variables and RFD were identified by 39 40 multivariate linear regression analysis and the model's goodness of fit was confirmed. Only tubular atrophy/interstitial fibrosis (T) had an accelerative direct effect on RFD, 41 while endocapillary hypercellularity (E) and active crescent (C) had an attenuating 42 43 indirect effect via ST. S had an attenuating indirect effect via eGFR. M had accelerative 44 indirect effect for RFD via UPE. Moreover, M and C had accelerative indirect effect via 45 UPE, which can be controlled by ST. However, both T and S had additional indirect accelerative effects via eGFR0c or MAP, which cannot be controlled by ST. SEM 46 identified a systemic path links between histological variables and RFD via dependent 47 clinical and/or treatment variables. These findings lead to clinically applicable novel 48

- 49 methodologies that can contribute to predict treatment outcomes using the Oxford
- 50 classifications.

# 51 Introduction

52	The international histological classification for IgA nephropathy (IgAN)
53	known as the Oxford classification was developed by defining and selecting relevant
54	pathological variables for renal functional decline (RFD). This classification utilizes
55	five pathological variables assessed individually: mesangial hypercellularity (M),
56	endocapillary hypercellularity (E), segmental glomerulosclerosis (S), tubular
57	atrophy/interstitial fibrosis (T), and cellular or fibrocellular (active) crescent (C) [1-3].
58	Almost all previous studies used traditional Cox regression analysis, which selects
59	independent prognostic variables to propose high-risk patients. However, the correlation
60	of the selected histological variables with clinical and/or treatment variables is
61	unknown, and this is important information when choosing therapy. As a consequence,
62	high-risk patients, irrespective of either active or chronic histological variables, equally
63	receive immunosuppressive treatment at the time of biopsy [4,5]. Due to a lack of
64	sufficient evidence for histology-based decision making, the Kidney Disease:
65	Improving Global Outcomes (KDIGO) guidelines recommend the choice of
66	immunosuppressant therapy be made, not based on histology, but mostly based on
67	clinical features indicating more than 1 g/d proteinuria around the time of biopsy and
68	during the two years after biopsy [6]. Therefore, risk stratification and treatment
69	decisions currently still rely on inaccurate categorization of these risk factors.
70	Recently, a new International Risk-Prediction Tool for IgAN has been
71	proposed as a more accurate tool to predict disease progression based on both
72	histological and clinical risk factors, including treatment choice [7-10]. This is a
73	personalized prediction model using an equation composed not only of clinical variables
74	including urine protein excretion (UPE), estimated glomerular filtration rate (eGFR),

75	and mean arterial pressure (MAP) at biopsy and treatment choice such as steroid
76	therapy (ST) and renin-angiotensin system blocker (RASB) but also the histological
77	variables MEST. This personalized equation predicts the probability of developing 50%
78	decrease in eGFR or end-stage renal disease in 5 years [8]. However, the formula is
79	composed of evenly evaluated histological, clinical, and treatment variables as a simple
80	summation in the exponential function [8,11]. Therefore, it is still not known how each
81	histological variable will respond to treatment choice after renal biopsy.
82	RFD is associated not only directly with histological, clinical, and/or treatment
83	variables, but also indirectly and unequally with clinical and/or treatment variables.
84	Structural equation modeling (SEM) is a method which can estimate these complex
85	interactions by adjusting for measurement errors in dependent variables using the error
86	term "ɛ," reducing bias in correlation estimates [12,13].
87	In this prospective study, we therefore aimed to use SEM with multivariate
88	linear regression analysis to find structural paths of correlation between each
89	histological variable and slope as a regression line of eGFR (SLOPE) via clinical
90	variables and treatment choice. The appropriately fitting model, including direct and
91	indirect effects on RFD of Oxford classification variables via clinical and/or treatment
92	variables, can then be implemented clinically.
93	
94	Materials and methods
95	Objectives

This was a prospective clinical study. Patients with IgAN were recruited and their clinical data and renal biopsy materials collected at 44 kidney centers across Japan. This clinical research project was produced by the ethical committee of The Research

Group on Progressive Renal Diseases organized by the Ministry of Health, Labour and
Welfare in Japan. The study protocol was in accordance with the standards of the ethics
committee at each center, and each patient consented to participate after being informed
of the purpose and procedure of the study.

Patients with IgAN registered between April 2005 and August 2015 in the 103 Japan IgA Nephropathy Prospective Cohort Study (JIGACS), which is a prospective 104 observational study conducted at facilities throughout Japan, were included in the study. 105 106 The protocol was approved by the Jikei University School of Medicine's Institutional 107 Review Board on Human Research, which acted as the main ethics committee for this study (No. 16-174 [4402]), Of 1130 patients, we excluded those with more than one of 108 109 the following variables missing: MESTC score, baseline UPE, eGFR, or MAP, and SLOPE measurements, or if they had no follow-up data after renal biopsy. Secondary 110 cases that showed mesangial IgA deposits, although with a predominant combined 111 112 disease such as diabetes mellitus, were excluded. After exclusions, 946 patients were included in the study. 113

### 114 Clinical data

Normally distributed variables, as determined using the Shapiro–Wilk test,
non-parametric variables and categorical variables were expressed as mean ± standard
deviation, as median and range, and as frequency and percentage, respectively. The data
were analyzed using SPSS version 24 (IBM Corp., USA).

119 Clinical variables, which were collected within 1 mo of biopsy and during 120 follow-up, were as follows. MAP was defined as diastolic pressure plus a third of the 121 pulse pressure. The eGFR was calculated as per the Japanese-based equation: eGFR 122  $(ml/min/1.73 m^2) = 194 \times serum creatinine (sCr)^{-1.094} \times age^{-0.287}$  (if female,  $\times 0.739$ )

123	[14]. In patients who were younger than 20 years, the eGFR was calculated
124	incorporating polynomial formulas for sCr and body length [15]. The Oxford study
125	excluded initial GFR <30 ml/min and initial proteinuria <0.5 mg/d, but no such
126	exclusion criteria were applied in this study. Treatments taken within a year after biopsy
127	were recognized as selected treatments: immunosuppressive treatment including ST
128	with/without tonsillectomy (reported as an intended treatment regardless of the type or
129	duration of therapy) or RASB indicating any exposure to angiotensin-converting
130	enzyme inhibitor, angiotensin receptor blockers, or both. If the patients had already
131	received RASB at the time of renal biopsy, this was also recorded as an initial
132	treatment. Weight, height, sCr, and amount of proteinuria (g/d) were also recorded.
133	Outcomes
134	In patients where more than two eGFR measurements were available, SLOPE
135	was calculated as a regression line and used as an outcome, as an indicator of RFD.
136	Pathological data
137	All cases were proven to be IgAN by biopsy. IgAN was defined by dominant
138	mesangial depositions of IgA and its presence in more than 10 glomeruli. Pathological
139	variables used in the present study included M0, M1, E0, E1, S0, S1, T0, T1, or T2, and
140	C0, C1, or C2, which were defined according to the Oxford classification [1-3]. Briefly,
141	M0 and M1 indicated the percentages of glomeruli with a mesangial hypercellularity of
142	0%–50% and <50%, respectively according to a simplification of the mesangial
143	hypercellularity score as shown in the Oxford study [1,2]. S0 or S1 and E0 or E1
144	indicated the absence or presence of S and E, respectively. T0, T1, and T2 indicated
145	interstitial fibrosis at 0%–25%, 26%–50%, and >50%, respectively. C0, C1, and C2
146	indicated the percentage of glomeruli with either a cellular or fibrocellular crescent at

147	0%, 1%–24%, and $\geq$ 25%, respectively. Renal biopsies were scored for pathological
148	variables according to the Oxford study by five renal pathologists (KJ, AH, AS, SH,
149	RK) blinded to the clinical data. When disagreement occurred between observers,
150	scoring was repeated by all five observers to reach a consensus. The agreement rate was
151	good or moderate in our previous study; the intraclass correlation coefficient of M, E, S,
152	T1/T2, and C1/C2 were 0.54, 0.57, 0.64, 0.72, and 0.57, respectively, among the five
153	pathologists [16].
154	SEM
155	SEM model building and estimation was done using STATA/SE version 15
156	(Light Stone, USA). A two-sided $P < 0.05$ was considered significant.
157	SEM included analysis of the direct paths between histological variables and
158	SLOPE and indirect paths between histological variables and SLOPE via clinical factors
159	and treatment choice, and linear regression analysis was used to find statistically
160	significant direct and indirect effects. Linear regression was used instead of Cox
161	regression to find indices of the model's statistical fit, as goodness of fit could not be
162	applied for the survival analysis model based on Cox multivariate analysis.
163	The candidate variables were selected according to a previous study by
164	Barbour et al. [8] We first created a hypothetical model consisting of all histological,
165	clinical, and treatment variables and SLOPE as a marker of RFD (Fig 1). Considering
166	normality, clinical variables were modified as follows: The baseline UPE0, baseline
167	square root eGFR0 (SReGFR0), and MAP at biopsy were centralized as each patient's
168	UPE0c, SReGFR0c, and MAPc, which was the value subtracted by an average of 946
169	patients in each category. Direct paths are indicated by arrows from each independent
170	histological variable (M, E, S, T, and C), clinical variable (centralized UPE [UPEc0],

171	centralized square root eGFR [SReGFR0c], or centralized MAP dichotomized with
172	negative MAPc as MAPc0 and positive MAPc as MAPc1 [MAPc01]), and treatment
173	variable (ST and RASB) after renal biopsy leading to SLOPE as an endpoint (Fig 1 a, b,
174	c). Indirect paths are indicated by arrows from each independent histological variable to
175	each mediating variable (clinical and treatment; Fig 1 d, e) and from each dependent
176	clinical variable to each dependent treatment variable (Fig 1 f). As MAP and eGFR can
177	affect the amount of proteinuria [6], the correlations between UPE0c and MAPc01 or
178	SReGFR0c were added as clinical variables. The correlations of a-f were estimated
179	using a multiple linear regression model. We reported standardized path coefficients
180	(SC), <i>P</i> values, and confidence intervals (CI). Additionally, error terms ( $\epsilon$ 1– $\epsilon$ 6), which
181	account for measurement error, were used in addition to latent clinical variables and
182	SLOPE.
183	
184	Fig 1. Hypothetical model incorporating all histological, clinical, and treatment

variables and the slope of change in estimated glomerular filtration rate (SLOPE),
as a marker of renal functional decline (RFD).

187

188 Direct paths are indicated as arrows from each independent histological variable (M, E,

189 S, T, or C), clinical variable (UPEc0, SReGFR0c, and MAPc01), and treatment variable

190 (ST with/without tonsillectomy and renin-angiotensin system blocker [RASB]) after

191 renal biopsy leading to SLOPE (Fig 1 a,b,c). Indirect paths are indicated as each

192 histological variable pointing to each mediating variable (clinical and treatment, Fig 1 d,

e) and pointing to each dependent treatment variable from each dependent clinical

194 variable (Fig 1 f).

195

196	These calculations using the hypothetical model identified significant
197	correlations among histological, clinical, and treatment variables and SLOPE, allowing
198	a new model to be drawn. Only paths with correlations of $P < 0.1$ were drawn as arrows
199	in this revised model. To determine any elimination bias, it was checked whether link
200	paths with correlations of $P < 0.1$ were the same as those with correlations of $P < 0.05$ .
201	An appropriately fitting model was proven using population error (root mean square
202	error of approximation [RMSEA] <0.05 with 90% CI), baseline comparison
203	(comparative fit index [CFI] >0.90), and size of residuals (standardized root mean
204	square residual [SRMSR] <0.05) [17-19]. The sample size of 946 observations for the
205	present analysis consisting of 19 variables including M0, M1, E0, E1, S0, S1, T0, T1 or
206	T2, C0, C1 or C2, UPE0c, SReGFR0c, MAPc0, MAPc1, ST0, ST1, RASB0, RASB1,
207	and SLOPE was appropriate because an ideal sample size-to-parameters ratio would be
208	20:1, indicating that the minimum sample size should be $19 \times 20$ [20].
209	
210	Results
211	Clinical profile
212	Clinical profiles of 946 Japanese with IgAN are shown in Table 1. Patients had
213	a median age of 37.1 years old (2.8-87.5 years old) and were followed up for a median
214	of 66 mo (1–174 mo). There was an equal distribution of males (49%) and females
215	(51%) indicating no gender-based skewing of the results. MAP at renal biopsy was

- 216 90.0±13.7 mmHg and dichotomized and centralized MAPc1 was 45%. eGFR0 was
- 217 75.6±28.9 ml/min and UPE0 was 1.1±2.2 mg/dl. Body mass index (BMI) was 22.1±3.8.

218 The SLOPE was -0.10±0.51 ml/min/1.73 m<sup>2</sup>/y.

# 219 Table 1. Clinical, treatment, and histological profiles of the IgAN patients in this

### 220 study.

Clinical profile		Histological profile	
			n (%)
Cohort	946	M	
Male, n (%)	463 (49%)	M0	671 (71%)
Female, n (%)	483 (51%)	M1	275 (29%)
Age	37.1 (2.8–87.5)	E	
Ethnicity	Japanese	E0	611 (65%)
MAP at biopsy (mmHg)	90.0 ± 13.7	E1	335 (35%)
MAPc01, n (%)		S	
Yes	430 (45%)	S0	247 (26%)
No	516 (55%)	S1	699 (74%)
eGFR (ml/min/1.73 m <sup>2</sup> )	75.6 ± 28.9	Т	
UPE0 (at biopsy)	1.1 ± 2.2	ТО	739 (78%)
BMI	22.1 ± 3.8	T1	170 (18%)
eGFR slope (ml/min/1.73m <sup>2</sup> /y)	$-0.10 \pm 0.51$	T2	37 (4%)
Period of follow-up (mo)	66 (1-174)	C	
		C0	580 (61%)
Treatment choice	n (%)	C1	357 (38%)
ST		C2	9 (1%)
Yes	605 (64%)		

No	341 (36%)	
RASB		
Yes	539 (57%)	
No	407 (43%)	

BMI: body mass index; eGFR: estimated glomerular filtration rate; MAP: mean arterial 221 pressure; MAPc01: centralized dichotomized MAP; RASB: renin-angiotensin system 222 blocker; ST: steroid therapy with/without tonsillectomy; UPE0: baseline urine protein 223 excretion. M0 and M1 indicated the percentages of glomeruli with a mesangial 224 225 hypercellularity of 0%–50% and <50%, respectively. S0 or S1 and E0 or E1 indicated the absence or presence of S and E, respectively. T0, T1, and T2 indicated interstitial 226 fibrosis at 0%-25%, 26%-50%, and >50%, respectively. C0, C1, and C2 indicated the 227 percentage of glomeruli with either a cellular or fibrocellular crescent at 0%, 1%–24%, 228 and  $\geq 25\%$ , respectively. 229

230

# 231 Treatment

Table 1 shows an overview of treatment choices for the study participants. ST was used to treat 64%, which included steroid pulse therapy in 20%, steroid pulse with tonsillectomy in 38%, oral steroid therapy in 5%, and oral steroids with tonsillectomy in 1%. RAS blockade was used to treat 57%. A small proportion (5%) was treated only with tonsillectomy, and 34% were not treated at all.

237 Pathological profile

Histological results from renal biopsy samples are shown in Table 1. The
proportion of the patients with M1, E1, S1, T1, T2, C1, and C2 was 29%, 35%, 74%,
18%, 4%, 38%, and 1%, respectively.

242	A hypothetical model was drawn as described in the Methods and tested with a
243	multivariate linear regression model using SEM (Fig 1). After removing non-significant
244	paths ( $P > 0.1$ ), SEM was performed again to find an appropriately fitting model. The
245	significant paths were the same whether the significance threshold was set at $P < 0.05$ or
246	P < 0.1 as shown in Fig 2. Therefore, no elimination bias was apparent. As indices of the
247	models' statistical fit, RMSEA, CFI, and SRMSR were 0.05 as same as 0.05, 0.93 as
248	more than 0.90, and 0.03 as less than 0.05, respectively. Therefore, these results indicate
249	that the model was an appropriate fit according to a likelihood estimation of appropriate
250	fit as shown in the Methods [17,18].
251	
252	Fig 2. SEM was performed to find an appropriate fitting model after removing
253	non-significant paths ( $P > 0.05$ ).
254	
255	Statistically significant paths between histological variables, clinical variables, or
256	treatment variables and SLOPE are shown as arrows with standardized coefficients
256 257	treatment variables and SLOPE are shown as arrows with standardized coefficients marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with
256 257 258	treatment variables and SLOPE are shown as arrows with standardized coefficients marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with SLOPE ( $P < 0.05$ ) (blue arrows). All histological variables showed indirect effects on
<ul><li>256</li><li>257</li><li>258</li><li>259</li></ul>	treatment variables and SLOPE are shown as arrows with standardized coefficients marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with SLOPE (P < 0.05) (blue arrows). All histological variables showed indirect effects on SLOPE via clinical variables or ST (red arrows).
<ul><li>256</li><li>257</li><li>258</li><li>259</li><li>260</li></ul>	<ul> <li>treatment variables and SLOPE are shown as arrows with standardized coefficients</li> <li>marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with</li> <li>SLOPE (P &lt; 0.05) (blue arrows). All histological variables showed indirect effects on</li> <li>SLOPE via clinical variables or ST (red arrows).</li> <li>Analyzing indirect contributors to SLOPE, ST, which correlated with S, E, C, UPE0c,</li> </ul>
<ul> <li>256</li> <li>257</li> <li>258</li> <li>259</li> <li>260</li> <li>261</li> </ul>	<ul> <li>treatment variables and SLOPE are shown as arrows with standardized coefficients</li> <li>marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with</li> <li>SLOPE (P &lt; 0.05) (blue arrows). All histological variables showed indirect effects on</li> <li>SLOPE via clinical variables or ST (red arrows).</li> <li>Analyzing indirect contributors to SLOPE, ST, which correlated with S, E, C, UPE0c,</li> <li>SReGFR0c, and MAPc01, was correlated with SLOPE. RASB, which correlated with</li> </ul>
<ul> <li>256</li> <li>257</li> <li>258</li> <li>259</li> <li>260</li> <li>261</li> <li>262</li> </ul>	<ul> <li>treatment variables and SLOPE are shown as arrows with standardized coefficients</li> <li>marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with</li> <li>SLOPE (P &lt; 0.05) (blue arrows). All histological variables showed indirect effects on</li> <li>SLOPE via clinical variables or ST (red arrows).</li> <li>Analyzing indirect contributors to SLOPE, ST, which correlated with S, E, C, UPE0c,</li> <li>SReGFR0c, and MAPc01, was correlated with SLOPE. RASB, which correlated with</li> <li>UPE0c, SReGFR0c, and MAPc01, was not correlated with SLOPE. The error terms ε1–</li> </ul>
<ul> <li>256</li> <li>257</li> <li>258</li> <li>259</li> <li>260</li> <li>261</li> <li>262</li> <li>263</li> </ul>	<ul> <li>treatment variables and SLOPE are shown as arrows with standardized coefficients</li> <li>marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with</li> <li>SLOPE (P &lt; 0.05) (blue arrows). All histological variables showed indirect effects on</li> <li>SLOPE via clinical variables or ST (red arrows).</li> <li>Analyzing indirect contributors to SLOPE, ST, which correlated with S, E, C, UPE0c,</li> <li>SReGFR0c, and MAPc01, was correlated with SLOPE. RASB, which correlated with</li> <li>UPE0c, SReGFR0c, and MAPc01, was not correlated with SLOPE. The error terms ε1–</li> <li>ε6 of each of MAPc01, SReGFR0c, UPEc0, ST, RASB, and SLOPE were 0.93, 0.68,</li> </ul>
<ol> <li>256</li> <li>257</li> <li>258</li> <li>259</li> <li>260</li> <li>261</li> <li>262</li> <li>263</li> <li>264</li> </ol>	<ul> <li>treatment variables and SLOPE are shown as arrows with standardized coefficients</li> <li>marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with</li> <li>SLOPE (P &lt; 0.05) (blue arrows). All histological variables showed indirect effects on</li> <li>SLOPE via clinical variables or ST (red arrows).</li> <li>Analyzing indirect contributors to SLOPE, ST, which correlated with S, E, C, UPE0c,</li> <li>SReGFR0c, and MAPc01, was correlated with SLOPE. RASB, which correlated with</li> <li>UPE0c, SReGFR0c, and MAPc01, was not correlated with SLOPE. The error terms ε1–</li> <li>ε6 of each of MAPc01, SReGFR0c, UPEc0, ST, RASB, and SLOPE were 0.93, 0.68,</li> <li>0.89, 0.88, 0.83, and 0.95, respectively.</li> </ul>

266	In the SEM analysis, statistically significant direct correlations with SLOPE (P
267	<0.05) were independent accelerative histological variable T, independent accelerative
268	clinical variables UPE0c and SReGFR0c, and independent attenuating treatment
269	variable ST. As well as the direct correlations with SLOPE, correlations between
270	clinical and histological variables and between treatment and histological variables or
271	clinical variables were calculated and indicated indirect correlations with SLOPE (Fig 2
272	and Table 2). UPE0c positively correlated with M and C and negatively correlated with
273	SReGFR0c. MAPc01 positively correlated with S and T. SReGFR0c negatively
274	correlated with S and T. ST negatively correlated with MAP01c and positively
275	correlated with UPE0c, SReGFR0c, S, E, and C. RASB, although correlated with
276	UPE0c, MAPc01, and SReGFR0c, was not an independent variable for SLOPE.
277	

Table 2. Direct and indirect correlations between histological variables and change
in estimated glomerular filtration rate (SLOPE) via clinical variables and
treatment variables.

	SC	SE	Z	P>z	[95% Confid	ence Interval]
SLOPE						
UPE0c	-0.073	0.033	-2.200	0.028	-0.138	-0.008
SReGFR0c	-0.224	0.039	-5.800	< 0.001	-0.299	-0.148
ST	0.127	0.032	3.99	< 0.001	0.065	0.19
Т	-0.095	0.038	-2.500	0.013	-0.170	-0.020
_cons	-0.318	0.056	-5.630	< 0.001	-0.429	-0.207
UPE0c						

SReGFR0c	-0.205	0.031	-6.660	< 0.001	-0.266	-0.145
М	0.194	0.031	6.26	< 0.001	0.133	0.254
С	0.102	0.031	3.31	0.001	0.042	0.162
_cons	-0.205	0.042	-4.870	< 0.001	-0.287	-0.122
MAPc01	1		I	1		
S	0.091	0.032	2.84	0.004	0.028	0.152
Т	0.237	0.03	7.79	< 0.001	0.177	0.297
_cons	0.637	0.066	9.61	< 0.001	0.507	0.766
SReGFR0c	1	I	<u> </u>	I		
S	-0.095	0.027	-3.52	< 0.001	-0.148	-0.042
Т	-0.545	0.021	-25.740	< 0.001	-0.587	-0.504
_cons	0.448	0.051	8.79	< 0.001	0.349	0.548
ST	1		I	I		
UPE0c	0.108	0.032	3.41	0.001	0.046	0.17
MAPc01	-0.069	0.033	-2.100	0.036	-0.133	-0.004
SReGFR0c	0.109	0.034	3.24	0.001	0.043	0.175
S	0.127	0.032	3.97	< 0.001	0.064	0.19
E	0.114	0.033	3.41	0.001	0.048	0.18
С	0.180	0.034	5.24	< 0.001	0.112	0.247
_cons	0.956	0.076	12.53	< 0.001	0.807	1.106
RASB						
UPE0c	0.088	0.03	2.88	0.004	0.028	0.147
MAPc01	0.207	0.031	6.61	0	0.146	0.269

SReGFR0c	-0.300	0.031	-9.550	0	-0.361	-0.238
_cons	0.976	0.049	19.87	0	0.88	1.072

SC: standardized coefficient; SE: standard error; T: tubular atrophy/interstitial fibrosis; M: mesangial hypercellularity; C: active crescent; S: segmental glomerulosclerosis; E: endocapillary hypercellularity; ST: steroid therapy including tonsillectomy; RASB: renin-angiotensin system blocker; UPE0c: centralized base line urine protein excretion; SReGFR0c: centralized square root baseline eGFR; MAPc01: centralized dichotomized baseline mean arterial pressure; cons: constant

287

As shown in Table 3, direct and/or indirect effects of histological variables on 288 SLOPE were calculated as total coefficients by combining the direct and indirect 289 290 coefficients for each histological variable (Table 3). The total coefficients were the sums of the direct and indirect coefficients, where each indirect coefficients of M, E, S, 291 292 T, or C in Table 3 was the integration of each coefficient of the clinical and treatment 293 variables in Table 2 according to the paths shown in Fig 2, which stood between histological variables and SLOPE (Fig 2). T showed an total accelerative effect 294 composed of the direct accelerative coefficient and the indirect accelerative coefficients 295 296 as via SReGFR0c and ST and via MAPc01 and ST. E showed an attenuating indirect effect via ST. C showed an attenuating indirect effect composed of an attenuating 297 indirect effect via ST and attenuating indirect effect via UPE0c and ST. S showed an 298 attenuating indirect effect via SReGFR0c and additionally an accelerative indirect effect 299 via SReGFR0c and ST, as well as via MAPc01 and ST. M showed an accelerative effect 300 301 composed of accelerative indirect effect via UPE0c and an attenuating indirect effect via UPE0c and ST (Table 3). In summary, only T showed an accelerative direct effect on 302

303	RFD, whereas E and C were not independent variables for RFD, correlated significantly
304	with ST, and showed attenuating effects on RFD via ST. S showed attenuating effects
305	on RFD via SReGFR0c. Both C and M had additional accelerative effects via UPE0c,
306	which can be controlled by ST, thus changing the accelerative effect to attenuating
307	effect. On the other hand, both T and S had additional indirect accelerative effects on
308	RFD via SReGFR0c or via MAPc01, which could not be controlled by ST, thus
309	continuing to exhibit the accelerative effect. The error terms $\varepsilon 1-\varepsilon 6$ of each MAPc01,
310	SReGFR0c, UPEc0, ST, RASB, and SLOPE were 0.93, 0.68, 0.89, 0.88, 0.83, and 0.95,
311	respectively (Fig 2).

Table 3. Direct and indirect effects of Oxford histological variables on change in
estimated glomerular filtration rate (SLOPE).

Histological	Direct	Indirect		Total
variable	coefficient	coefficient	via	coefficient
Μ		-0.014	UPE0c	-0.011
Μ		0.003	UPE0c, ST	
E		0.014	ST	0.014
S		0.021	SReGFR0c	0.019
S		-0.001	SReGFR0c, ST	
S		-0.001	MAPc01, ST	
Т	-0.095			-0.105
Т		-0.008	SReGFR0c, ST	
Т		-0.002	MAPc01, ST	
С		0.023	ST	0.024

	C 0.001 UPE0c, ST
315	M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental
316	glomerulosclerosis; T: tubular atrophy/interstitial fibrosis; C: active crescent;
317	SReGFR0c: centralized square root baseline eGFR; MAPc01: centralized dichotomized
318	baseline mean arterial pressure; UPE0c: centralized baseline urine protein excretion;
319	ST: steroid therapy including tonsillectomy
320	
321	Discussion
322	In this prospective multicenter study involving 946 Japanese IgAN patients, we
323	applied SEM to evaluate structural correlations associated with the change in eGFR as
324	RFD (SLOPE). Consequently, this analysis showed systemic path links between
325	SLOPE and histological variables via clinical and/or treatment variables.
326	We identified the contributors to SLOPE as T (T1 or T2, independent
327	accelerative histological variable), SReGFR0c and UPE0c (independent accelerative
328	clinical variables), and ST (independent attenuating treatment variable). RASB was not
329	an independent variable for SLOPE. Further, the selected contributors as well as the
330	independent variables for SLOPE were connected via dependent histological, clinical,
331	and/or treatment variables. Therefore, we investigated the statistically significant
332	structural correlations among the histological, clinical, and treatment variables and

333 SLOPE.

Using the coefficients of the direct and indirect correlations, we calculated the
total effect of each histological variable on SLOPE (Table 3). T was the only
histological variable with a direct (accelerative) effect on SLOPE. It had additional
indirect effects (accelerative) via SReGFR0c or MAPc01, which could not be controlled

338	by ST, thus maintaining the accelerative effect. Both E and C attenuated SLOPE via ST.
339	M showed an overall accelerative effect on SLOPE, thereby incorporating an
340	accelerative effect via UPE0c. Further, both M and C had additional accelerative effects
341	on SLOPE via UPE0c, which was controlled by ST, thereby transforming the
342	accelerative effect to attenuating effect. S had an attenuating indirect effect via eGFR.
343	Moreover, both T and S had indirect accelerative effects via eGFR0c or MAP, which
344	could not be controlled by ST, thus continuing with the accelerating effect. If S0
345	developed to S1, SReGFR0c decreased (Table 2). This negative correlation meant that if
346	eGFR at biopsy was high, SLOPE declined strongly, while if it was low, there was a
347	weaker decline. This is also true in normal kidneys [21].
348	The above findings suggest that ST was chosen for patients with E1 and C1 or
349	C2 but not with T1 or T2 and that it effectively attenuated decline in eGFR. This is in
350	partial agreement with another Japanese study, which found that patients with E1, S1, or
351	C1 treated with ST had significantly better prognosis than the non-treatment group [22].
352	Similarly, in two other studies, the presence of E was strongly associated with
353	subsequent ST, and there was a higher rate of decline in renal function in patients who
354	were not treated with immunosuppressants [1] or corticosteroids [23]. Our study also
355	showed that C and M had additional accelerating effects via UPE0c on SLOPE, which
356	were controlled and thus led to the change from accelerative to attenuating effect by ST.
357	Therefore, ST can be considered to be effective for the patients with C and M by
358	diminishing the accelerative effect of UPE0c. Other studies have shown that patients
359	had an increased risk of disease progression with extremely increasing C, even with
360	immunosuppression [5,24,25]. T and S had additional accelerative effects via SReGFR0
361	or MAPc01, which could not be controlled by ST. This is consistent with the previous

362	findings, which reported that S (as well as M and T) had predictive prognostic value for
363	RFD [1,5,23]. However, the prognostic role of S1 for RFD can be small, when early ST
364	prevented a progression from active crescent as C1/C2 to S. M appears to be a sensitive
365	histological variable, as it can also be a risk factor for RFD via acceleration of
366	proteinuria, when proteinuria cannot be controlled by ST [5,26,27]. However, the
367	original Oxford study selected S1 and T1/T2 but not M1 for RFD in a multivariate
368	linear regression model adjusted for initial eGFR, MAP, and UPE0 [1,28]. The
369	VALIGA study suggested also M1 was a steroid-responsive variable [26,29,30]. These
370	conflicting results illustrate the benefit of analyzing both the direct and indirect effects.
371	We were able to stratify the Oxford histological classifications from the
372	viewpoint of treatment response in predicting future outcomes. Several validation
373	studies of the Oxford classification using Cox analysis showed merely different
374	independent histological, clinical, and treatment variables without suggesting their
375	concrete clinical use, which may depend on differences in the cohorts [4,5,31,32]. SEM
376	can clarify these differences by analyzing the correlations between Oxford histological
377	variables and RFD via clinical and treatment variables.
378	In conclusion, SEM identified a systemic path links between histological
379	variables and RFD via dependent clinical and/or treatment variables. To the best of our
380	knowledge, there has been no such systematic research previously to propose the

correlation among histological, clinical, and treatment variables in depth. These findings
lead to clinically applicable novel methodologies that can contribute to predict treatment

383 outcomes using the Oxford classifications and improve care for IgAN patients using

384 personalized medicine.

# 386 Acknowledgments

- 387 We thank the study participants for their kind cooperation. The authors would like to
- thank Enago (www.enago.jp) for the English Language review.
- 389

# References

- Working Group of the International Ig ANN, Cattran DC, Coppo R, Cook HT,
   Feehally J, Roberts IS, et al. The Oxford classification of IgA nephropathy:
   rationale, clinicopathological correlations, and classification. Kidney Int.
   2009;76: 534-45.
- Working Group of the International Ig ANN, Roberts IS, Cook HT, Troyanov S,
   Alpers CE, Amore A, et al. The Oxford classification of IgA nephropathy:
   pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:
   546-56.
- 398 3. Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU, et al. A
  multicenter study of the predictive value of crescents in iga nephropathy. J Am
  Soc Nephrol. 2017;28: 691-701.
- 401 4. Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular
  402 diseases: clinicopathologic correlations, limitations exposed by validation
  403 studies, and suggestions for modification. Kidney Int. 2014;85: 779-93.
- Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford
  Classification of IgA nephropathy 2016: an update from the IgA Nephropathy
  Classification Working Group. Kidney Int. 2017;91: 1014-21.
- Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al.
  Management and treatment of glomerular diseases (part 1): conclusions from a

- 409 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
  410 Conference. Kidney Int. 2019;95: 268-80.
- 411 7. Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J,
- 412 et al. The MEST score provides earlier risk prediction in lgA nephropathy.
- 413 Kidney Int. 2016;89: 167-75.
- 8. Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al.
  Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA
  Intern Med. 2019;179: 942-52.
- Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, et al. Improving
  treatment decisions using personalized risk assessment from the International
  IgA Nephropathy Prediction Tool. Kidney Int. 2020;98: 1009-19.
- 420 10. Barbour SJ, Feehally J. Predicting the future in immunoglobulin A nephropathy:
  421 a new international risk prediction tool. Nephrol Dial Transplant. 2020;35:
  422 379-82.
- 423 11. Zhang Y, Guo L, Wang Z, Wang J, Er L, Barbour SJ, et al. External validation
  424 of international risk-prediction models of IgA nephropathy in an
  425 Asian-Caucasian cohort. Kidney Int Rep. 2020;5: 1753-63.
- 426 12. Gardiner L, Akintola A, Chen G, Catania JM, Vaidya V, Burghardt RC, et al.
  427 Structural equation modeling highlights the potential of Kim-1 as a biomarker
  428 for chronic kidney disease. Am J Nephrol. 2012;35: 152-63.
- Chen HW, Chen YC, Yang FM, Catania JM, Vaidya V, Burghardt RC, et al.
  Mediators of the effects of gender on uric acid nephrolithiasis: a novel
  application of structural equation modeling. Sci Rep. 2018;8: 6077.

- 432 14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised
  433 equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis.
  434 2009;53: 982-92.
- Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al.
  Creatinine-based equation to estimate the glomerular filtration rate in Japanese
  children and adolescents with chronic kidney disease. Clin Exp Nephrol.
  2014;18: 626-33.
- Hisano S, Joh K, Katafuchi R, Shimizu A, Hashiguchi N, Kawamura T, et al.
  Reproducibility for pathological prognostic parameters of the Oxford
  classification of IgA nephropathy: a Japanese cohort study of the Ministry of
  Health, Labor and Welfare. Clin Exp Nephrol. 2017;21: 92-6.
- Rakotoasimbola E, Blili S. Measures of fit impacts: Application to the causal
  model of consumer involvement. Int J Mark Res. 2018;61: 77-92.
- Kline RB. Principles and practice of structural equation modeling. 4th ed. New
  York: Guilford Press; 2016.
- Tripathy JP, Thakur JS, Jeet G, Jain S. Structural equation modeling to identify
  the risk factors of diabetes in the adult population of North India. Trop Med
  Health. 2018;46: 23.
- 450 20. Fan X, Thompson B, Wang L. Effects of sample size, estimation methods, and
  451 model specification on structural equation modeling fit indexes. Struct Equ
  452 Modeling. 2009;6: 56-83.
- 453 21. Baba M, Shimbo T, Horio M, Ando M, Yasuda Y, Komatsu Y, et al.
  454 Longitudinal study of the decline in renal function in healthy subjects. PLoS
  455 One. 2015;10: e0129036.

456 22. Moriyama T, Karasawa K, Miyabe Y, Akiyama K, Ogura S, Takabe T, et al.

- 457 Validation of the revised Oxford classification for IgA nephropathy considering
- 458 treatment with corticosteroids/immunosuppressors. Sci Rep. 2020;10: 11151.
- 459 23. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al.
  460 Validation of the Oxford classification of IgA nephropathy. Kidney Int.
  461 2011;80: 310-7.
- 462 24. Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, et al. Evaluation of the
  463 Oxford Classification of IgA nephropathy: a systematic review and
  464 meta-analysis. Am J Kidney Dis. 2013;62: 891-9.
- 465 25. Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study
  466 of oxford classification of IgA nephropathy: the significance of extracapillary
  467 proliferation. Clin J Am Soc Nephrol. 2011;6: 2806-13.
- Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al.
  Validation of the Oxford classification of IgA nephropathy in cohorts with
  different presentations and treatments. Kidney Int. 2014;86: 828-36.
- 471 27. Yang P CX, Zeng L, Hao H, Xu G. The response of the Oxford classification to
- 472 steroid in IgA nephropathy: a systematic review and meta-analysis. Oncotarget.
  473 2017;8: 59748-56.
- 474 28. Yoon CY, Chang TI, Kang EW, Lim BJ, Kie JH, Kee YK, et al. Clinical
  475 usefulness of the Oxford classification in determining immunosuppressive
  476 treatment in IgA nephropathy. Ann Med. 2017;49: 217-29.
- 477 29. Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, et al. Is
  478 there long-term value of pathology scoring in immunoglobulin A nephropathy?

479	A validation study of the Oxford Classification for IgA Nephropathy (VALIGA)
480	update. Nephrol Dial Transplant. 2020;35: 1002-9.

- 481 30. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA
- 482
- study. J Am Soc Nephrol. 2015;26: 2248-58. 483
- Moriyama T. Clinical and histological features and therapeutic strategies for IgA 484 31. nephropathy. Clin Exp Nephrol. 2019;23: 1089-99. 485
- 486 32. Joh K, McNamara K. Differences of histological classification between the
- Japanese Histological Grade Classification and the Oxford Classification. In: 487
- Tomino, editor. Pathogenesis and treatment in IgA nephropathy. Splinger: 488
- 489 Tokyo, Japan; 2016. p 69-87.



Fig.2



Fig.1